Radio Cadena Agramonte emisiora de Camagüey
Havana, Jan 28.- Miguel Díaz-CanelBermúdez, First Secretary of the Central Committee of the Communist Party of Cuba and President of the Republic, chaired a meeting with health experts and scientists this Tuesday. It was reported that the country has entered a zone of epidemiological safety following a decrease in reports of febrile syndromes and arboviruses, according to sources from the Presidency.
Dr. Carilda Peña García, Vice Minister of Public Health, stated that in the third week of the year, cases of febrile syndrome decreased by 29.3 percent compared to the previous week, with a sustained reduction in suspected and confirmed cases of dengue and chikungunya for three consecutive weeks.
Dr. RaúlGuinovartDíaz, Director of Science and Technology at the University of Havana, presented mathematical models confirming the downward trend in all regions, with a greater impact in the western and central parts of the country.
The specialists agreed that, despite the results, the population must maintain risk awareness and comply with hygienic-sanitary measures.
Díaz-Canel emphasized the systematic nature of self-monitoring (autofocal control) and the use of adulticides, actions supported by guaranteed resources for the anti-vector campaign in the first half of the year, including larvicide cycles.
The meeting also addressed the development of biosimilar drugs by the Biotechnology and Pharmaceutical Industries Group, Biocubafarma.
Dr. Ricardo Silva Rodríguez, an executive of the entity, explained that biosimilars are products equivalent to reference biologics, with the same structure, safety, and efficacy, available at lower costs.
He noted that the international boom in these drugs is concentrated in oncology, autoimmunity, hematology, and metabolic disorders—areas in which Cuba participates with products such as EPOCIM, Leukocim, Heberon Alfa R, PEG-Heberon, human albumin, and Enoxaparin sodium.
Silva Rodríguez reported that Biocubafarma's strategy for the 2025–2035 period includes the development of 19 biosimilars and generics, with the aim of expanding access within the National Health System and strengthening the Group's export portfolio. (ACN) (Photo: Taken from Presidency)
